Multivir, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Website
- http://multivir.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- MultiVir, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03544723
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center | Northwestern University, Chicago, Illinois, United States
🇺🇸Rush University Cancer Center, Chicago, Illinois, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Phase 1
Terminated
- Conditions
- Recurrent Head and Neck CancerMetastatic Solid Tumor Cancer
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- MultiVir, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02842125
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
News
No news found